期刊名称：CURRENT TOPICS IN MEDICINAL CHEMISTRY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Current Topics in Medicinal Chemistry is a popular forum for the review of areas of keen and topical interest to medicinal chemists and others in allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review will assemble each issue.
The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships.
Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute in a major way to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.
Instructions to Authors
Review article/manuscripts with prior approval should be submitted to the Editor-in-Chief at the following address:
Dr. Allen B. Reitz,
Senior Research Fellow,
Johnson & Johnson Pharmaceutical Research and Development,
Spring House, Pennsylvania 19477, USA.
Tel: +1-215-628-5615;
Fax, +1-215-628-4985;
Email, areitz@prius.jnj.com or reitz12000@yahoo.com
Established researchers are encouraged to submit proposals for suitable themes for future issues to the Editor-in-Chief. The proposal should outline the intended contents and coverage of the issue along with a proposed list of authors and titles. All major topics in the field of medicinal chemistry and related areas may be submitted to the journal. If approved by the Editor-in-Chief, the Guest Editor should then solicit authors to write the reviews, set deadlines, and follow-through as appropriate. The Guest Editors will have the discretion to write a review in their issue, but they are not essentially required to do so.
The manuscripts for the review articles, written in English, should not exceed 60 pages in length (ca. 30 printed pages) and can be as short as a maximum of 30 pages in length (ca. 15 printed pages) for “mini-reviews? The manuscripts should be typed double-space throughout on A-4 or American quarto paper. Dot matrix or any other print that is difficult to read is unacceptable. Two copies of each manuscript must accompany the original along with a passport size black-and-white photograph of the authors and a computer disk, and should be sent to the Editor-in-Chief. All pages should be numbered. Abbreviations should be defined the first time that they are used in the manuscript, and a list of abbreviations should also be provided.
Manuscript Organization. The manuscript should be divided as: Title Page, Abstract and the main text. The text may be subdivided further according to the areas to be discussed. This should be followed by the Acknowledgements (if any) and Reference sections. The first page should contain the title, the authors?names, with an asterisk marking the name of the corresponding author.
Abstract. The abstract should not exceed 250 words and it should condense the essential features of the review article, with the focus on the major advances in the field.
Key Words: Authors must supply up to eight key words along with their manuscript.
Text. The main text should begin on a separate page and it may be subdivided into separate sections. The review article should mention any previous important reviews and contain a comprehensive discussion starting with the general background of the field. It should then go on to discuss the salient features of recent developments, and also the challenges and opportunities of the future research. The authors should avoid presenting material which has already been published in any previous review. The reference numbers should be given in square brackets in the text. Acknowledgements should be kept to a minimum.
Tables:
* Data Tables should be submitted in Microsoft Excel or in Microsoft Word table format.
* Each table should include a title/caption explaining what the table shows. Detailed legends may then follow.
* Tables should be given on separate pages with indications on the left hand margin to the text, as to the appropriate placement of the tables.
* Tables should not contain vertical rules.
* Columns and rows of data should be made visibly distinct by ensuring the borders of each cell display as black lines.
* Tables should be numbered consecutively in order of their citation in the body of the text, with Arabic numerals.
* If a reference is cited in both the table and text, insert a lettered footnote in the table to refer to the numbered reference in the text.
* Tabular data provided as additional files can be submitted as an Excel spreadsheet.
Figures / Illustrations:
All authors must strictly follow the guidelines below for preparing illustrations for publication in Current Topics in Medicinal Chemistry.
Editorial Requirements:
The quality of the illustrations printed in the journal largely depends on the quality of the figures/illustration provided by the author. In preparing artwork or graphics for publication, keep in mind the following points.
* Submit the original artwork or a photographic print of the original for publication.
* Do not submit photocopies. (Hardcopy submission requirement)
* Illustrations should be provided as separate files, not embedded in the text. (Hardcopy submission requirement).
* Remove all color from graphics except for those illustrations (Greyscale), which are intended to be printed in color.
* Good quality of hardcopy originals are a requirement.
* Figures/illustrations cannot be modified or enhanced by the journal production staff.
* Figures should be referred to as “Fig. (1)? “Fig. (2)?etc. in the text with figure numbers in bold within round bracket.
* Revised manuscripts should contain a complete set of artwork and photographs.
Technical Details:
* Figures should be provided on high quality, white, smooth opaque paper. (Hardcopy requirement)
Format & Resolution:
* The following file formats can be accepted. (Preference in order of appearance): PDF, TIFF, JPEG, GIF
* Illustrations must fit a single or double column format on the journal page, according to the following guideline below:
HEIGHT
WIDTH
SINGLE COLUMN
24 cm (max)
8.5 cm (max)
DOUBLE COLUMN
24 cm (max)
18 cm (max)
* Whenever possible, submit graphics that do not have to be reduced to fit the standard figure size.
* Use the best resolution available (hardcopy submission requirement). For online submission the maximum resolution is 300 dpi.
* Avoid textures and shadings giving a three-dimensional effect to the illustration.
* Symbols and lettering in the illustration should be of similar size.
* Smaller lettering is used.
* Font: Times New Roman or Helvetica is preferable. Font size: 10pt (maximum)
* Line drawings should have clear and sharp lines and should be of uniform density. Moreover, lines should be continuous without any breaks.
* Do not use lines thinner than 1 point.
Color Figures/Illustrations:
* Free colored artwork will only be published if the color is deemed scientifically necessary by the Editor-in-Chief.
* One color plate will be published free of charge in each article. The cost for the first additional published page of color figures is US$ 605; the second additional page will be for US$ 440, and each subsequent page for $ 303.
* Color figures should be supplied in CMYK not RGB colors.
* Required resolution for online submission is 300 dpi. In case of hardcopy submission, please use the maximum resolution available.
Photographs:
Submit high-contrast prints that are of single- or double-column width so that they will not have to be reduced when printed. Negatives are not acceptable. However, in case of hardcopy submission, color illustrations and plates can be published from 35 mm color slides.
Chemical Structures: Chemical structures must be prepared according to the guidelines below.
Structures should be prepared using a suitable drawing program e.g. ChemDraw and provided as separate file, submitted both on disk and in printed formats.
Numbers in bold should identify all chemical structure. If a name is also used to describe the compound, the associated number in bold should be in parenthesis, e.g. “compound (1)?
Structure Drawing Preferences:
[As according to the ACS style sheet]
Drawing Settings:
Chain angle 120o
Bond spacing 18% of width
Fixed length 14.4 pt (0.500cm, 0.2in)
Bold width 2.0 pt (0.071cm, 0.0278in)
Line width 0.6 pt (0.021cm, 0.0084in)
Margin width 1.6 pt (0.096cm)
Harsh spacing 2.5 pt (0.088cm, 0.0347in)
Text settings:
Font Times New Roman / Helvetica
Size 10pt
Under the Preference Choose:
Units points
Tolerances 3 pixels
Under Page Setup Use:
Paper US letter
Scale 100%
References. All references must be numbered in the text in square brackets, e.g. [4], or [7,10-15], in the order of citation in the text. Titles of journals are abbreviated according to the format required for the Journal of Medicinal Chemistry with inclusive pagination and the titles of the articles included. Examples:
[1] Pitts, W. J.; Wityak, J.; Smallheer, J. M.; Tobin, A. E.; Jetter, J. W.; Boynitzky, J. S.; Harlow, P. P.; Solomon, K. A.; Corjay, M. H.; Mousa, S. A.; Wexler, R. R.; Jadhav, P. K. Isoxazolines as Potent Antagonists of the Integrin avb3. J. Med. Chem. 2000, 43, 27-40.
[2] Mšhler, H.; Okada, T. Benzodiazepine Receptors: Demonstrat
Editorial Board
J. Adams (Univ. of Southern California, Los Angeles, CA, USA)
R.B. de Alancastro (Univ.-Ilha do Fundao, Rio de Janeiro, Brasil)
J. Aube (Univ. of Kansas, Lawrence, KS, USA)
M. Avery (Univ. of Mississippi, University, MS, USA)
E.J. Barreiro (Federal Univ. of Rio de Janeiro, Rio de Janeiro, Brasil)
E. Baxter (Johnson & Johnson Pharm. R & D, Spring House, PA, USA)
P.R. Bernstein (AstraZeneca, Wilmington, DE, USA)
J.M. Cook (Univ. of Wisconsin, Milwaukee, WI, USA)
N. Cosford (Merck Res. Lab, San Diego, CA, USA)
A.K. Debnath (Lindsley F. Kimball Res. Inst., New York, NY, USA)
E.B. De Souza (Synaptic Pharm. Corp., Paramus, NJ, USA)
R.H. Dodd (Institute de Chimie des Substances Naturelles, Gif-Sur-Yvette, France)
A. Espinosa Ubeda (Facultad de Farmacia, Granada, Espana)
M. Fernandez Zertuche (Univ. Autonoma Del Edo. De Morelos, Morelos, Mexico)
G.I. Georg (Univ. of Kansas, Lawrence, KS, USA)
S.W. Gerritz (Glaxo SmithKline, Research Triangle Park, NC, USA)
C. Gilon (The Hebrew University, Jerusalem, Israel)
R.A. Glennon (Virginia Commonwealth Univ., Richmond, VA, USA)
M. Goodman (Univ. of California, San Diego, CA, USA)
G.S. Hamilton (Guilford Pharmaceutical, Inc., Baltimore, MD, USA)
G. Hartman (Merck Res. Lab., West Point, PA, USA)
P.A. Hipskind (Lilly Research Laboratories, Indianapolis, IN, USA)
W.J. Hoekstra (Glaxo SmithKline, Research Triangle Park, NC, USA)
R.L. Hudkins (Cephalon, Inc., West Chester, PA, USA)
K.A. Jacobson (National Inst. of Health, Bethesda, MD, USA)
F. Janssens (Johnson & Johnson Pharm. R & D, Beerse, Belgium)
E. Juaristi (CINVESTAV-IPN, Mexico, Mexico)
Michael E. Jung (Univ. of California Los Angeles, Los Angeles, CA, USA)
S.W. Kaldor (Lilly Corporate Center, Indianapolis, IN, USA)
C.P. Kordik (Johnson & Johnson Pharm. R&D, Spring House, PA, USA)
A.P. Kozikowski (Georgetown University, Washington, DC, USA)
L. Ren-li (Peking University, Beijing, China)
J.A. Lowe (Pfizer, Inc., Croton, CT, USA)
M. Macielag (Johnson & Johnson Pharm. R & D, Raritan, NJ, USA)
B.E. Maryanoff (Johnson & Johnson Pharm. R & D, Spring House, PA, USA)
O.R. Martin (Universite d’Orleans, Orleans, France)
D.D. Miller (University of Tennessee, Memphis, TN, USA)
G. Molander (University of Pennsylvania, Philadelphia, PA, USA)
M. Murcko (Vertex Pharmaceuticals, Cambridge, MA, USA)
N. Neamati (Univ. of Southern California, Los Angeles, CA, USA)
M.H. Norman (Amgen, Inc., Thousand Oaks, CA, USA)
I. Ojima (State University of New York, Stony Brook, NY, USA)
R. Pelliciari (Univ. di Perugia, Perugia, Italy)
K.C. Rice (National Institute of Health, Bethesda, MD, USA)
A. Saab (Wyeth-Ayerst Research, Princeton, NJ, USA)
S.M. Sieburth (Temple University, Philadelphia, PA, USA)
B.B. Snider (Brandeis University, Waltham, MA, USA)
S. Street (Pfizer Global R & D, Sandwich, UK)
J.P. Vacca (Merck Res. Laboratories, West Point, PA, USA)
L. Zang (Peking University, Beijing, China)
N.S. Zefirov (Lenin Hills, Moscow, Russia)
|
